Jazz Pharmaceuticals plc (NASDAQ: JAZZ) kicked off on Monday, up 20.57% from the previous trading day, before settling in for the closing price of $141.07. Over the past 52 weeks, JAZZ has traded in a range of $95.49-$148.06.
A company in the Healthcare sector has dropped its sales by -1.00% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -62.01%. With a float of $57.84 million, this company’s outstanding shares have now reached $60.74 million.
Jazz Pharmaceuticals plc (JAZZ) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Jazz Pharmaceuticals plc is 4.82%, while institutional ownership is 98.77%. The most recent insider transaction that took place on Nov 17 ’25, was worth 1,204,573. Before that another transaction happened on Oct 03 ’25, when Company’s Director sold 3,500 for $140.00, making the entire transaction worth $490,000. This insider now owns 408,826 shares in total.
Jazz Pharmaceuticals plc (JAZZ) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported 6.6 earnings per share (EPS), higher than consensus estimate (set at 5.81) by 0.79. Wall Street market experts anticipate that the next fiscal year will bring earnings of 4.45 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -62.01% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 5.94% during the next five years compared to -1.00% drop over the previous five years of trading.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Trading Performance Indicators
Take a look at Jazz Pharmaceuticals plc’s (JAZZ) current performance indicators. Last quarter, stock had a quick ratio of 1.44. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.49. Likewise, its price to free cash flow for the trailing twelve months is 7.73.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -6.07, a number that is poised to hit 6.41 in the next quarter and is forecasted to reach 22.56 in one year’s time.
Technical Analysis of Jazz Pharmaceuticals plc (JAZZ)
Let’s dig in a bit further. During the last 5-days, its volume was 2.08 million. That was better than the volume of 0.92 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 83.11%.
During the past 100 days, Jazz Pharmaceuticals plc’s (JAZZ) raw stochastic average was set at 95.85%, which indicates a significant increase from 93.61% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 5.31 in the past 14 days, which was higher than the 3.37 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $134.88, while its 200-day Moving Average is $122.37. However, in the short run, Jazz Pharmaceuticals plc’s stock first resistance to watch stands at $174.47. Second resistance stands at $178.84. The third major resistance level sits at $184.78. If the price goes on to break the first support level at $164.16, it is likely to go to the next support level at $158.22. Assuming the price breaks the second support level, the third support level stands at $153.85.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Key Stats
The company with the Market Capitalisation of 10.34 billion has total of 60,765K Shares Outstanding. Its annual sales at the moment are 4,069 M in contrast with the sum of 560,120 K annual income. Company’s last quarter sales were recorded 1,126 M and last quarter income was 251,410 K.
